<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Felodipine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Felodipine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Felodipine: Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="11734" href="/d/html/11734.html" rel="external">see "Felodipine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="86263" href="/d/html/86263.html" rel="external">see "Felodipine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52866881"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Felodipine;</li>
<li>Plendil;</li>
<li>SANDOZ Felodipine</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F170395"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antihypertensive;</li>
<li>
                        Calcium Channel Blocker;</li>
<li>
                        Calcium Channel Blocker, Dihydropyridine</li></ul></div>
<div class="block doa drugH1Div" id="F170354"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c9faf53d-a9f0-466d-bc7e-f2d52d10e458">Chronic stable angina</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic stable angina (alternative agent) (off-label use)</b>: <b>Note:</b> A beta-blocker is the preferred initial therapy; if there are ongoing symptoms on beta-blocker therapy, a calcium channel blocker (typically a dihydropyridine [eg, felodipine]) may be added; felodipine may be used as an alternative therapy if there are contraindications or unacceptable adverse effects with beta-blockade (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23166211']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23166211'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 5 to 10 mg once daily; if initiated at 5 mg, increase dose to 10 mg once daily as tolerated after 2 to 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9402450','lexi-content-ref-10220634','lexi-content-ref-8881845']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9402450','lexi-content-ref-10220634','lexi-content-ref-8881845'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bc4b3de7-1b7f-4f34-9c5e-fb2c0aab85f9">Hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension: Note:</b> For initial treatment in patients with blood pressure ≥20/10 mm Hg above goal, may be used in combination with another appropriate agent (eg, ACE inhibitor, ARB, or thiazide diuretic). For patients &lt;20/10 mm Hg above goal, some experts recommend an initial trial of monotherapy; however, over time, many patients will require combination therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356','lexi-content-ref-Mann.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356','lexi-content-ref-Mann.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 2.5 to 5 mg once daily; titrate every 1 to 2 weeks as needed based on patient response; usual dose range: 2.5 to 10 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356','lexi-content-ref-Mann.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356','lexi-content-ref-Mann.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991795"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doha drugH1Div" id="F50988927"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Initial: 2.5 mg once daily; monitor blood pressure closely during titration.</p></div>
<div class="block doe drugH1Div" id="F170355"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">
<b>Hypertension:</b> Oral: Consider lower initial doses (eg, 2.5 mg once daily) and titrate at no less than 2-week intervals to response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21518977']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21518977'])">Ref</a></span>).</p></div>
<div class="block dop drugH1Div" id="F4473156"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="86263" href="/d/html/86263.html" rel="external">see "Felodipine: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bc4b3de7-1b7f-4f34-9c5e-fb2c0aab85f9">Hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension:</b> Limited data available: Children ≥6 years and Adolescents: Oral: Initial: 2.5 mg once daily; may increase as needed at 2-week intervals to a maximum daily dose: 10 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28827377','lexi-content-ref-NHLBI.1','lexi-content-ref-12700955']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28827377','lexi-content-ref-NHLBI.1','lexi-content-ref-12700955'])">Ref</a></span>)</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51263610"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric specific recommendations available; based on experience in adult patients, no dosage adjustments necessary; use with caution.</p></div>
<div class="block dohp drugH1Div" id="F51130523"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric specific recommendations available; based on experience in adult patients, initial dosage adjustments suggested; monitor blood pressure closely during titration.</p></div>
<div class="block adr drugH1Div" id="F170318"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema (2% to 17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (11% to 15%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%: Cardiovascular: Flushing (4% to 7%), tachycardia (≤3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Abdominal pain, acid regurgitation, anemia, angina pectoris, angioedema, anxiety disorder, arm pain, arthralgia, back pain, bronchitis, bruise, cardiac arrhythmia, cardiac failure, cerebrovascular accident, chest pain, constipation, decreased libido, depression, diarrhea, dizziness, drowsiness, dyspnea, dysuria, epistaxis, erythema, extrasystoles, facial edema, flatulence, flu-like symptoms, flushing, foot pain, gingival hyperplasia, gynecomastia, hip pain, hypersensitivity angiitis, hypotension, impotence, influenza, insomnia, irritability, knee pain, leg pain, muscle cramps, myalgia, myocardial infarction, nausea, nervousness, palpitations, paresthesia, pharyngitis, polyuria, psoriasis (Song 2021), respiratory tract infection, sinusitis, syncope, urinary frequency, urinary urgency, urticaria, visual disturbance, vomiting, xerostomia</p></div>
<div class="block coi drugH1Div" id="F170331"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to felodipine or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to other dihydropyridines; women of childbearing potential, in pregnancy, and during lactation.</p></div>
<div class="block war drugH1Div" id="F170315"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Angina/MI: Increased angina and/or MI has occurred with initiation or dosage titration of dihydropyridine calcium channel blockers; reflex tachycardia may occur resulting in angina and/or MI in patients with obstructive coronary disease especially in the absence of concurrent beta-blockade.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypotension/syncope: Symptomatic hypotension with or without syncope can rarely occur; blood pressure must be lowered at a rate appropriate for the patient's clinical condition.</p>
<p style="text-indent:-2em;margin-left:4em;">• Peripheral edema: The most common side effect is peripheral edema (dose dependent); occurs within 2 to 3 weeks of starting therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Aortic stenosis: Use with extreme caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure: The ACC/AHA heart failure guidelines recommend to avoid use in patients with heart failure (HF) due to lack of benefit and/or worse outcomes with calcium channel blockers in general (AHA/ACC/HFSA [Heidenreich 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; may require lower starting dose.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Initiate at a lower dose in the elderly.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage forms specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Lactose: May contain lactose; if necessary, consider alternative agents in patients intolerant of lactose.</p></div>
<div class="block foc drugH1Div" id="F170324"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg, 5 mg, 10 mg</p></div>
<div class="block geq drugH1Div" id="F170311"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F170334"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Felodipine ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $1.22 - $1.58</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $1.08 - $1.58</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $2.18 - $3.72</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866882"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Plendil: 2.5 mg, 5 mg, 10 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg, 5 mg, 10 mg</p></div>
<div class="block adm drugH1Div" id="F170328"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Swallow tablet whole; tablet should not be divided, crushed, or chewed. May be administered without food or with a small meal that is low in fat and carbohydrates.</p>
<p style="text-indent:-2em;margin-left:2em;">Bariatric surgery: Tablet, extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. No IR formulation exists. Consider switching to a different dihydropyridine calcium channel blocker that is available in IR formulation.</p></div>
<div class="block admp drugH1Div" id="F52612816"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Swallow tablet whole; do not divide, crush, or chew. May be administered without food or with a small meal that is low in fat and carbohydrates.</p></div>
<div class="block use drugH1Div" id="F170327"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Hypertension:</b> Management of hypertension</p></div>
<div class="block off-label drugH1Div" id="F52980505"><span class="drugH1">Use: Off-Label: Adult</span><p>Chronic stable angina</p></div>
<div class="block mst drugH1Div" id="F170402"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Plendil may be confused with Isordil, pindolol, Pletal, PriLOSEC, Prinivil</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F170389"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2D6 (weak)</p></div>
<div class="block dri drugH1Div" id="F170320"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atosiban: Calcium Channel Blockers may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Salts: May diminish the therapeutic effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetidine: May increase the serum concentration of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clopidogrel: Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Felodipine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Felodipine. Management: Consider alternatives to this combination when possible. If combined, monitor for reduced felodipine efficacy and the need for felodipine dose increases.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Felodipine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Felodipine. Management: Consider using lower felodipine doses when combined with strong CYP3A4 inhibitors. Monitor patients for increased felodipine effects and toxicities (eg, hypotension, edema) when combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dantrolene: May enhance the hyperkalemic effect of Calcium Channel Blockers. Dantrolene may enhance the negative inotropic effect of Calcium Channel Blockers.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: May enhance the orthostatic hypotensive effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: May enhance the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grapefruit Juice: May increase the serum concentration of Felodipine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Increasing Effects: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhalational Anesthetics: May enhance the hypotensive effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: May increase the serum concentration of Felodipine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): May increase the serum concentration of Felodipine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the adverse/toxic effect of Calcium Channel Blockers (Dihydropyridine). Specifically, the risk of hypotension or muscle weakness may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Melatonin: May diminish the antihypertensive effect of Calcium Channel Blockers (Dihydropyridine).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents (Nondepolarizing): Calcium Channel Blockers may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazosin: Antihypertensive Agents may enhance the hypotensive effect of Prazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide.  Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talazoparib: Felodipine may increase the serum concentration of Talazoparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terazosin: Antihypertensive Agents may enhance the hypotensive effect of Terazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: CYP2D6 Inhibitors (Weak) may increase the serum concentration of Thioridazine.  Management: Consider avoiding concomitant use of thioridazine and weak CYP2D6 inhibitors. If combined, monitor closely for QTc interval prolongation and arrhythmias. Some weak CYP2D6 inhibitors list use with thioridazine as a contraindication.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urapidil: Antihypertensive Agents may enhance the hypotensive effect of Urapidil. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F170345"><span class="drugH1">Food Interactions</span>
<p style="text-indent:-2em;margin-left:2em;">Food: Compared to a fasted state, felodipine peak plasma concentrations are increased up to twofold when taken after a meal high in fat or carbohydrates. Grapefruit juice similarly increases felodipine C<sub>max</sub> by twofold. Increased therapeutic and vasodilator side effects, including severe hypotension and myocardial ischemia, may occur. Management: May be taken with a small meal that is low in fat and carbohydrates. Monitor hemodynamic response closely in patients consuming grapefruit juice concurrently; felodipine dosage adjustment and/or modification of grapefruit juice ingestion may be needed.</p></div>
<div class="block rep_considerations drugH1Div" id="F58484033"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Medications considered acceptable for the treatment of chronic hypertension during pregnancy may generally be used in patients trying to conceive. Felodipine is generally not considered a preferred agent for use in pregnant patients (ACC/AHA [Whelton 2018]; ACOG 2019; NICE 2019); however, use of felodipine may be considered (ESC [Cífková 2020]).</p></div>
<div class="block pri drugH1Div" id="F170335"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events were observed in animal reproduction studies.</p>
<p style="text-indent:0em;margin-top:2em;">Chronic maternal hypertension is associated with adverse events in the fetus/infant. Chronic maternal hypertension may increase the risk of birth defects, low birth weight, premature delivery, stillbirth, and neonatal death. Actual fetal/neonatal risks may be related to the duration and severity of maternal hypertension. Untreated chronic hypertension may also increase the risks of adverse maternal outcomes, including gestational diabetes, preeclampsia, delivery complications, stroke, and myocardial infarction (ACOG 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Patients with preexisting hypertension may continue their medication during pregnancy unless contraindications exist (ESC [Regitz-Zagrosek 2018]). When treatment of hypertension is initiated during pregnancy, agents other than felodipine may be preferred (ACOG 2019; ESC [Regitz-Zagrosek 2018]; SOGC [Magee 2022]); however, use of felodipine may be considered (ESC [Cífková 2020]).</p></div>
<div class="block brc drugH1Div" id="F16354859"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if felodipine is present in breast milk.</p>
<p style="text-indent:0em;margin-top:2em;">Due to the potential for serious adverse reactions in the breastfeeding infant, the manufacturer recommends a decision be made whether to discontinue breastfeeding or to discontinue the drug, considering the importance of treatment to the mother. Use of a calcium channel blocker other than felodipine may be preferred in lactating patients (ESC [Cífková 2020]).</p></div>
<div class="block dic drugH1Div" id="F170336"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">May be taken with a small meal that is low in fat and carbohydrates.</p></div>
<div class="block mop drugH1Div" id="F51344354"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">BP; heart rate; peripheral edema.</p></div>
<div class="block pha drugH1Div" id="F170314"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits calcium ions from entering the “slow channels” or select voltage-sensitive areas of vascular smooth muscle and myocardium during depolarization, producing a relaxation of coronary vascular smooth muscle and coronary vasodilation; increases myocardial oxygen delivery in patients with vasospastic angina</p></div>
<div class="block phk drugH1Div" id="F170330"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Antihypertensive: 2 to 5 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration of antihypertensive effect: 24 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: 100%; Absolute: 20% due to first-pass effect </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: &gt;99% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic; CYP3A4 substrate (major); extensive first-pass effect </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Immediate release: 11 to 16 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak: 2.5 to 5 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (70% as metabolites); feces 10%</p></div>
<div class="block phksp drugH1Div" id="F51153945"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Felodipine clearance is reduced about 60% in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Plasma concentrations of felodipine increase with advancing age. Clearance of felodipine in elderly hypertensive patients was 45% of that observed in young volunteers. Steady-state mean area under curve in young patients was 39% of that observed in elderly patients.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F170337"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Plendil</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Munobal | Plendil</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Felodipin arcana | Felodipin hexal pharma | Felodipin ratiopharm | Felodistad | Munobal | Plendil</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Agon | Felodil | Felodur | Fendex | Plendil</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Felodipine bexal | Felodipine eg | Felodipine eurogenerics | Felodipine merck-generics | Felodipine ratiopharm | Felodipine Sandoz | Plendil | Renedil</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Auronal | Felicipin | Felodipine ratiopharm | Felohexal | Plendil | Presid</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Felodipin 1 A Pharma | Felodipin Helvepharm | Felodipin Mepha | Felodipin retard zentiva | Plendil Plain</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Splendil</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Bo fei ke | Etersim | Ke li ping | Li nuo | Lian huan er ding | Plendil</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Auronal | Felodipin | Felodipin al | Plendil | Presid</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Felo biochemie | Felo-puren | Felobeta | Felocor | Felodipin | Felodipin 1 A Pharma | Felodipin Actavis | Felodipin al | Felodipin dura | Felodipin Heumann | Felodipin ratiopharm | Felodipin sandoz | Felodipin stada | Felodipin von CT | Felogamma | Modip | Munobal | Plendil</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Felodipin 1a farma</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Feldipina | Plendil</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Plendil</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Felodipin | Felodipin Alpharma | Felodipin hexal | Plendil | Presid</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Felocor | Felodipin stada | Healthplend | Plendil | Plentopine</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Fensel | Perfudal | Plendil</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Felodipin Alpharma | Felodipin hexal | Felodipin ratiopharm | Felodipin sandoz | Hydac | Plendil | Sekal</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Felodipine Sandoz</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Cabren | Cardioplen xl | Delofine xl | Felendil xl | Felodipine arrow | Felodipine cox | Felodipine focus | Felodipine kent | Felodipine Sandoz | Felogen xl | Felotens xl | Folpik | Keloc | Neofel | Neofel xl | Parmid XL | Pinefeld xl | Plendil | Plendil old | Vascalpha</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Plendil</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apt Felodipine | Fedisyn | Felogard | Felostad | Plendil</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Auronal | Felodipin ratiopharm | Felodipin winthrop | Plendil | Presid</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Nirmadil | Plendil</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Plendil</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Penedil</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Felogard | Plendil | Renedil</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Feldil</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Feloday | Felodipina Mylan | Felodipina provissoria | Felodipina Sandoz | Felodipina Winthrop | Plendil | Prevex</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Plendil</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Catrazil | Munobal | Splendil</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Enfelo | Plendil</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Adipin | Aprogen felodipine | Binex felodipine | Decreapin | Decreapin sr | Dilopin | Feldipin | Fellon | Felobal | Feloden | Felodic | Felodin | Felodion | Felodip | Felodpine sik | Felopine | Feloten | Felotin | Fenodipine | Haifel | Halopin | Hidipin | Hidropin sr | Hydipin | Hydropine | Keydipin | L dipine er | L-dipine | Lodil | Lodipin | Lowperin | Munobal | Munodipine | Samik felodipine | Selepin | Splendil er | Stapin | Vaspine er | Zirodipine</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Plendil</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Plendil</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Felodipin Actavis | Felodipinhexal | Plendil | Presid</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Felodipin | Felodipine eg | Plendil | Renedil</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Felodipin | Felodipin hexal | Plendil | Presid</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Eutens | Fedin | Felodipino | Felodipino raam | Feymutur | Glitazor | Hofodilan | Ivenkens | Munobal | Plendil | Tecnoplex | Xysvol</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Felocor | Plendil</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Plendil</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Felodipine Actavis | Plendil | Preslow</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Felodipin | Felodipin hexal | Felodipin ratiopharm | Plendil</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Agon | Felo | Plendil er</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Plendil</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Dilahex | Dilofen | Feldona 5 er | Felim | Felocard | Felodin | Felodipin Natrapharm | Feloence 5 er | Felojen | Felop | Felostal | Felostar | Lodistad er | Lodistad mr | Lupress | Plendil er | Ropine er | Versant xr</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Plendil</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Plendil</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Plendil</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Felodipina</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Flindip | Plendil</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Felodipin al | Felodipin sandoz | Felohexal</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Felodip | Felodipin sz | Plendyl</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Plendil</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Felodipin Actavis | Felodipin bijon | Felodipin gea | Felodipin hexal | Felodipin mylan | Felodipin ratiopharm | Felodipin stada | Plendil</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Felodipin stada | Plendil</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Felodipin | Plendil | Presid</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Enfelo | Felim | Felodipin stada | Felodipine Sandoz | Felohexal | Feloten | Munobal | Plendil</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Plendil</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Fedil | Fedisyn | Felo | Felop | Felopine | Felpin | Plendil | Polo | Stapin | Winlopine | Yalop</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Felodip | Felohexal</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Plendil</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Munobal | Plendil</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Mibeplen</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Felodipine hexal | Plendil</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-30575676">
<a name="30575676"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG practice bulletin no. 203: chronic hypertension in pregnancy. <i>Obstet Gynecol</i>. 2019;133(1):e26-e50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/felodipine-drug-information/abstract-text/30575676/pubmed" id="30575676" target="_blank">30575676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21518977">
<a name="21518977"></a>Aronow WS, Fleg JL, Pepine CJ, et al, ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. <i>Circulation.</i> 2011;123(21):2434-2506.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/felodipine-drug-information/abstract-text/21518977/pubmed" id="21518977" target="_blank">21518977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Chobanian.1">
<a name="Chobanian.1"></a>Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. <i>JAMA.</i> 2003;289(19):2560-2571.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31841131">
<a name="31841131"></a>Cífková R, Johnson MR, Kahan T, et al. Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension. <i>Eur Heart J Cardiovasc Pharmacother</i>. 2020;6(6):384-393. doi:10.1093/ehjcvp/pvz082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/felodipine-drug-information/abstract-text/31841131/pubmed" id="31841131" target="_blank">31841131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9264493">
<a name="9264493"></a>Cohn JN, Ziesche S, Smith R, et al. Effect of the Calcium Antagonist Felodipine as Supplementary Vasodilator Therapy in Patients With Chronic Heart Failure Treated With Enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. <i>Circulation.</i> 1997;96(3):856-863.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/felodipine-drug-information/abstract-text/9264493/pubmed" id="9264493" target="_blank">9264493</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9402450">
<a name="9402450"></a>Dunselman P, Liem AH, Verdel G, Kragten H, Bosma A, Bernink P. Addition of felodipine to metoprolol vs replacement of metoprolol by felodipine in patients with angina pectoris despite adequate beta-blockade. Results of the Felodipine ER and Metoprolol CR in Angina (FEMINA) Study. Working Group on Cardiovascular Research, The Netherlands (WCN). <i>Eur Heart J</i>. 1997;18(11):1755-1764.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/felodipine-drug-information/abstract-text/9402450/pubmed" id="9402450" target="_blank">9402450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10220634">
<a name="10220634"></a>Emanuelsson H, Egstrup K, Nikus K, et al. Antianginal efficacy of the combination of felodipine-metoprolol 10/100 mg compared with each drug alone in patients with stable effort-induced angina pectoris: a multicenter parallel group study. The TRAFFIC Study Group. <i>Am Heart J</i>. 1999;137(5):854-862.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/felodipine-drug-information/abstract-text/10220634/pubmed" id="10220634" target="_blank">10220634</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Felodipine.1">
<a name="Felodipine.1"></a>Felodipine [prescribing information]. Las Vegas, NV: Yiling Pharmaceutical Inc; July 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Felodipine.2">
<a name="Felodipine.2"></a>Felodipine extended-release tablets (USP) [prescribing information]. Carlsbad, CA: Carlsbad Technology Inc; March 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23166211">
<a name="23166211"></a>Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. <i>Circulation.</i> 2012;126(25):3097-3137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/felodipine-drug-information/abstract-text/23166211/pubmed" id="23166211" target="_blank">23166211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28827377">
<a name="28827377"></a>Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. <i>Pediatrics</i>. 2017;140(3).<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/felodipine-drug-information/abstract-text/28827377/pubmed" id="28827377" target="_blank">28827377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26934393">
<a name="26934393"></a>Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/felodipine-drug-information/abstract-text/26934393/pubmed" id="26934393" target="_blank">26934393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24243703">
<a name="24243703"></a>Go AS, Bauman M, King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention [published online November 15, 2013]. <i>Hypertension</i>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/felodipine-drug-information/abstract-text/24243703/pubmed" id="24243703" target="_blank">24243703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35363499">
<a name="35363499"></a>Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. <i>Circulation</i>. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/felodipine-drug-information/abstract-text/35363499/pubmed" id="35363499" target="_blank">35363499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24352797">
<a name="24352797"></a>James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). <i>JAMA</i>. 2014;311(5):507-520.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/felodipine-drug-information/abstract-text/24352797/pubmed" id="24352797" target="_blank">24352797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33637192">
<a name="33637192"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. <i>Kidney Int</i>. 2021;99(3S):S1-S87. doi:10.1016/j.kint.2020.11.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/felodipine-drug-information/abstract-text/33637192/pubmed" id="33637192" target="_blank">33637192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2016700">
<a name="2016700"></a>Lombardi T, Fiore-Donno G, Belser U, et al. Felodipine-Induced Gingival Hyperplasia: A Clinical and Histologic Study. <i>J Oral Pathol Med.</i> 1991;20(2):89-92.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/felodipine-drug-information/abstract-text/2016700/pubmed" id="2016700" target="_blank">2016700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35577426">
<a name="35577426"></a>Magee LA, Smith GN, Bloch C, et al. Guideline no. 426: hypertensive disorders of pregnancy: diagnosis, prediction, prevention, and management. <i>J Obstet Gynaecol Can.</i> 2022;44(5):547-571.e1. doi:10.1016/j.jogc.2022.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/felodipine-drug-information/abstract-text/35577426/pubmed" id="35577426" target="_blank">35577426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mann.1">
<a name="Mann.1"></a>Mann JFE, Flack JM. Choice of drug therapy in primary (essential) hypertension. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 7, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7574861">
<a name="7574861"></a>Moncica I, Oh PI, ul Qamar I, et al. A crossover comparison of extended release felodipine with prolonged action nifedipine in hypertension. <i>Arch Dis Child</i>. 1995;73(2):154-156.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/felodipine-drug-information/abstract-text/7574861/pubmed" id="7574861" target="_blank">7574861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NHLBI.1">
<a name="NHLBI.1"></a>National Heart, Lung, and Blood Institute. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. Clinical Practice Guidelines, 2011, National Institutes of Health. <a href="http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf" target="_blank">http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15286277">
<a name="15286277"></a>National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. <i>Pediatrics.</i> 2004;114(2)(suppl):555-576.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/felodipine-drug-information/abstract-text/15286277/pubmed" id="15286277" target="_blank">15286277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2019">
<a name="NICE.2019"></a>NICE guideline hypertension in pregnancy: diagnosis and management. https://www.nice.org.uk/guidance/ng133. Published June 25, 2019. Accessed December 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24589852">
<a name="24589852"></a>Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-2492. doi: 10.1161/CIR.0000000000000029.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/felodipine-drug-information/abstract-text/24589852/pubmed" id="24589852" target="_blank">24589852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Plendil.1">
<a name="Plendil.1"></a>Plendil (felodipine) [prescribing information]. Wilmington, DE: AstraZeneca LP; October 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/felodipine-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8881845">
<a name="8881845"></a>Rønnevik PK, Silke B, Ostergaard O. Felodipine in addition to beta-adrenergic blockade for angina pectoris. a multicentre, randomized, placebo-controlled trial. <i>Eur Heart J</i>. 1995;16(11):1535-1541.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/felodipine-drug-information/abstract-text/8881845/pubmed" id="8881845" target="_blank">8881845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34611920">
<a name="34611920"></a>Song G, Yoon HY, Yee J, Kim MG, Gwak HS. Antihypertensive drug use and psoriasis: a systematic review, meta- and network meta-analysis. <i>Br J Clin Pharmacol</i>. Published online October 5, 2021. doi:10.1111/bcp.15060<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/felodipine-drug-information/abstract-text/34611920/pubmed" id="34611920" target="_blank">34611920</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8135450">
<a name="8135450"></a>Steele RM, Schuna AA, Schreiber RT. Calcium Antagonist-Induced Gingival Hyperplasia. <i>Ann Intern Med.</i> 1994;120(8):663-664.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/felodipine-drug-information/abstract-text/8135450/pubmed" id="8135450" target="_blank">8135450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12700955">
<a name="12700955"></a>Trachtman H, Frank R, Mahan JD, et al. Clinical trial of extended-release felodipine in pediatric essential hypertension. <i>Pediatr Nephrol.</i> 2003;18(6):548-553.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/felodipine-drug-information/abstract-text/12700955/pubmed" id="12700955" target="_blank">12700955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24341872">
<a name="24341872"></a>Weber MA, Schiffrin EL, White WB, et al, Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hypertens (Greenwich)</i>. 2014;16(1):14-26.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/felodipine-drug-information/abstract-text/24341872/pubmed" id="24341872" target="_blank">24341872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29133356">
<a name="29133356"></a>Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Hypertension</i>. 2018;71(6):e13-e115. doi:10.1161/HYP.0000000000000065<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/felodipine-drug-information/abstract-text/29133356/pubmed" id="29133356" target="_blank">29133356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9675532">
<a name="9675532"></a>Young PC, Turiansky GW, Sau P, et al. Felodipine-Induced Gingival Hyperplasia. <i>Cutis.</i> 1998;62(1):41-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/felodipine-drug-information/abstract-text/9675532/pubmed" id="9675532" target="_blank">9675532</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8438 Version 388.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
